Aldosterone receptor antagonists in the medical management of chronic heart failure

Mayo Clinic Proceedings

Volumn 80, Issue 12, 2005, Pages 1623-1630

  Tang, W H Wilson ^a   Parameswaran, Anoop C ^a   Maroo, Anjli P ^a   Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ACUTE HEART INFARCTION; AMENORRHEA; CLINICAL TRIAL; COMORBIDITY; DIASTOLIC HEART FAILURE; DRUG MECHANISM; GYNECOMASTIA; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERKALEMIA; HYPOKALEMIA; IMMUNOMODULATION; KIDNEY FAILURE; MASTALGIA; RECEPTOR BINDING; REVIEW; SYSTOLIC HEART FAILURE;

EID: 28544447015     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/80.12.1623     Document Type: Review

References (74)

1. Francis GS, Tang WH. Pathophysiology of congestive heart failure. Rev Cardiovasc Med. 2003;4(suppl 2):S14-S20.
2. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs. 1994;47:586-598.
3. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984;101:370-377.
4. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int. 1987;31:1402-1415.
5. Hensen J, Abraham WT, Durr JA, Schrier RW. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol. 1991;11:441-446.
6. Cogan MG. Angiotensin JJ: a powerful controller of sodium transport in the early proximal tubule. Hypertension. 1990;15:451-458.
7. Quan A, Baum M. Regulation of proximal tubule transport by angiotensin II. Semin Nephrol. 1997;17:423-430.
8. Smith AG. Spironolactone in the long-term management of patients with congestive heart failure. Curr Med Res Opin. 1980;7:131-136.
9. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
10. Pitt B, Zannad F, Remme WJ, et al, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
11. Pitt B, Remme W, Zannad F, et al, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [published correction appears in N Engl J Med. 2003;348:2271]. N Engl J Med. 2003;348:1309-1321.
12. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg. 1964;107:159-172.
13. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670.
14. Swedberg K, Eneroth P, Kjekshus J, Snapinn S, CONSENSUS Trial Study Group. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). Am J Cardiol. 1990;66:40D-44D.
15. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation. 1990;82:1730-1736.
16. Weber MA. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension. Am J Hypertens. 1999;12(12, pt 3):189S-194S.
17. Weber MA, Neutel JM, Smith DH. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition. Am Heart J. 1992;123:1414-1420.
18. Weber MA. Clinical implications of aldosterone blockade. Am Heart J. 2002;144(5, suppl):S12-S18.
19. Purdy RE, Weber MA. Enhancement and prolongation of vascular smooth muscle contraction by aldosterone. Blood Vessels. 1983;20:34-43.
20. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
21. Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993;33:40-45.
22. Tang WH, Vagelos RH, Yee YG, et al. Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure [published correction appears in J Am Coll Cardiol. 2002;39:746]. J Am Coll Cardiol. 2002;39:70-78.
23. McKelvie RS, Yusuf S, Pericak D, et al, RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056-1064.
24. Packer M, Poole-Wilson PA, Armstrong PW, et al, ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.
25. NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J. 1998;19:481-489.
26. Cicoira M, Zanolla L, Franceschini L, et al. Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2002;89:403-407.
27. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail. 1999;1:401-406.
28. Silvestre JS, Robert V, Heymes C, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem. 1998;273:4883-4891.
29. Gomez-Sanchez CE, Zhou MY, Cozza EN, Monta H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997;138:3369-3373.
30. Takeda Y, Miyamori I, Inaba S, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension. 1997;29(1, pt 1):45-48.
31. Rossi GP, Andreis PG, Neri G, et al. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase-dependent signaling pathways. J Investig Med. 2000;48:343-350.
32. Urata H, Nishimura H, Ganten D, Arakawa K. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press Suppl. 1996;2:22-28.
33. Schersten B, Thulin T, Kuylenstierna J, et al. Clinical and biochemical effects of spironolactone administered once daily in primary hypertension: multicenter Sweden study. Hypertension. 1980;2:672-679.
34. Lavenius B, Hansson L. A double-blind comparison of spironolactone and hydrochlorothiazide in hypertensive patients treated with metoprolol. Int J Clin Pharmacol Ther Toxicol. 1982;20:291-295.
35. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther. 2003;25:2388-2404.
36. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003;92:38-42.
37. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation. 2000;102:2325-2328.
38. Korkmaz ME, Muderrisoglu H, Ulucam M, Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol. 2000;86:649-653.
39. Ramires FJ, Mansur A, Coelho O, et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
40. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37:1800-1807.
41. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279-1285.
42. Dyckner T, Wester PO, Widman L. Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive heart failure and/or arterial hypertension. Eur J Clin Pharmacol. 1986;30:535-540.
43. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
44. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 1999;22:17-22.
45. Degre S, Detry JM, Unger P, Cosyns J, Brohet C, Kormoss N. Effects of spironolactone-altizide on left ventricular hypertrophy. Acta Cardiol. 1998;53:261-267.
46. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
47. Zannad F, Alia F, Dousset B, Perez A, Pitt B, RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES) [published correction appears in Circulation. 2001;103:476]. Circulation. 2000;102:2700-2706.
48. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559-2565.
49. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res. 1997;35:30-34.
50. Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001;141:41-46.
51. Le J, Rudolph A, Moe G, et al. Treatment with eplerenone, an aldosterone antagonist improved ventricular remodeling and function post myocardial infarction [abstract]. J Am Coll Cardiol. 2002;41(suppl A):182A. Abstract 1135-88.
52. Tsutamoto T, Wada A, Maeda K, et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228-1233.
53. Cicoira M, Zanolla L, Rossi A, et al. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304-310.
54. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
55. Ahokas RA, Warrington KJ, Gerling IC, et al. Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res. 2003;93:e124-e135.
56. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev. 2001;19:185-200.
57. Zillich AJ, Carter BL. Eplerenone-a novel selective aldosterone blocker. Ann Pharmacother. 2002;36:1567-1576.
58. Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg. 2002;95:39-41.
59. Tamirisa KP, Aaronson KD, Cody RJ, Koelling TM. Spironolactone induced renal impairment and hyperkalemia in patients with heart failure: can we predict these side effects? [abstract]. J Am Coll Cardiol. 2003;41(suppl A):162A. Abstract 1085-73.
60. Blaustein DA, Babu K, Reddy A, Schwenk MH, Avram MM. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol. 2002;90:662-663.
61. Obialo Q, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85 years with subclinical renal disease. Am J Cardiol. 2002;90:663-665.
62. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart. 2001;85:E8.
63. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110:438-441.
64. Svensson M, Gustafsson F, Galatius S, Atar D, Hildebrandt PR. Hyperkalemia and impaired renal function during treatment with spironolactone in patients with congestive heart failure: figures from a real world scenario [abstract]. J Am Coll Cardiol. 2003;41(suppl A):265A. Abstract 1106-123.
65. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
66. Tang WH, Francis GS. Spironolactone in chronic heart failure: all's well that ends well [editorial]. J Am Coll Cardiol. 2003;41:215-216.
67. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005;112:39-47.
68. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
69. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol. 2000;11:A0828.
70. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res. 2002;25:837-842.
71. Grandi AM, Imperiale D, Santillo R, et al. Aldosterone antagonist im-proves diastolic function in essential hypertension. Hypertension. 2002;40:647-652.
72. Yamada T, Shimonagata T, Kumagai K, et al. The effects of the concomitant use of carvedilol and spironolactone in patients with mild to moderate congestive heart failure [abstract]. Circulation. 2002;106(suppl 2):II-353. Abstract 1762.
73. Cicoira M, Zanolla L, Rossi A, et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol. 2001;37:1808-1812.
74. Rousseau MF, Gume O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy [published correction appears in J Am Coll Cardiol. 2003;42:1865]. J Am Coll Cardiol. 2002;40:1596-1601.